Startup
Description
Novamigra Therapeutics is an innovative pharmaceutical company and a spin-out of VRG Therapeutics, dedicated to the development of patient-centric therapies for migraine prevention. By leveraging novel mechanisms of action and rigorous translational science, the company aims to address the significant unmet needs in migraine prophylaxis and improve long-term outcomes for patients worldwide.
Migraine is a chronic neurological disorder affecting approximately one billion people worldwide. Around 40% of patients require preventive therapy, yet currently available treatments often show limited efficacy, poor tolerability, or high rates of non-response. Approximately 40–50% of patients fail to achieve a clinically meaningful reduction in migraine frequency, highlighting a substantial unmet medical need for more effective and better-tolerated preventive options.
VRG-145 is being developed to address this gap through a differentiated mechanism of action, positioning it as a potential next-generation therapy for patients who do not benefit adequately from current standards of care.
Based on regulatory guidance with the FDA and NNGYK, Novamigra has finalized the design of its first-in-human Phase 1b study, a 36 healthy volunteer trial designed to assess the pharmacokinetics and safety of VRG-145. The FIH is expected to start in late 2026.
The company is led by a multidisciplinary team, bringing prior experience from leading organizations including AbbVie, Lilly, and the FDA, with a strong track record of advancing migraine-focused programs.
